retatrutide phase 2 nejm weight loss 48 weeks percent Achieves Large Decreases in Patients Without Diabetes: TRIUMPH-1 Retatrutide Phase 2 NEJM Trial:

For type 2 diabetes, NICE (NG28) recommends continuing GLP-1 therapy only if patients achieve both a reduction in HbA1c of at least 11 mmol/mol (1.0%) AND at least 3% weight loss after 6 months

This supplement is designed for those who need higher doses of glutathione for detoxification and immune support

31 (Suppl 2): S395S404

What the Numbers Show Average weight loss by timepoint: Week 12: 8.7% total body weight (19 pounds for 220-pound person) Week 24: 17.3% total body weight (38 pounds for 220-pound person) Week 36: 21.1% total body weight (46 pounds for 220-pound person) Week 48: 24.2% total body weight (53 pounds for 220-pound person) Data from Phase 2 clinical trial, 12mg dose cohort